Regeneron Releases Phase 2 Trial Results and Shares Next Steps

Regeneron Pharmaceuticals recently published results from LUMINA-1, a clinical trial that investigated the safety and effect of garetosmab (also named REGN2477) in people with FOP. Results from the Phase 2 trial showed that garetosmab achieved an approximately 90% reduction in new heterotopic bone formation as measured by two imaging techniques. The majority of adverse events were judged to be mild to moderate in severity. You can read more about the LUMINA-1 clinical trial on or about the results with garetosmab from Regeneron’s press release.

As noted in the press release, Regeneron plans to review the clinical data results with regulators to determine next steps for developing this investigational therapy. 

Read the January 9, 2020 press release >

Make a Difference

Donate Connect Fundraise

Already a Member? Sign In

Sign Up for FOP Connection, Our Monthly eNewsletter